Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$0.16
EPS est.
$0.16
EPS surprise
+0.00%
1-day move
+3.93%
ADMA Biologics, Inc. reported an EPS of $0.16, matching expectations, which contributed to a positive stock reaction, with shares rising by 3.93%. However, revenue details were not disclosed, leaving some uncertainty about overall performance. The lack of guidance may lead investors to remain cautious as they await further information.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.16 | N/A | +0.00% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
ADMA Biologics, Inc. is a biotechnology company focused on developing and manufacturing specialty plasma-derived biologics. With a market cap of $2 billion, it plays a crucial role in providing therapies for patients with immune deficiencies and other serious conditions, which is particularly important in the healthcare sector.
Last quarter
In Q1-2026, ADMA reported an EPS of $0.19, which was in line with expectations. The stock reacted negatively, dropping 1.66% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+23.07%
Avg 1-day reaction
+0.64%
Overall, expectations for ADMA's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are keen to see if the company can maintain its growth trajectory.
Bull case
If ADMA can demonstrate strong revenue growth and positive updates on its product pipeline, it could lead to increased investor confidence and a potential stock price rally.
Bear case
Conversely, if the company reports disappointing earnings or lacks clarity on future growth, it may lead to a sell-off, especially given the high implied volatility in the options market.
The print will turn on these.
Q1
What is the expected revenue growth for the upcoming quarter?
Revenue growth will be a critical indicator of ADMA's market performance and ability to capitalize on demand for its products.
Q2
Are there any updates on the product pipeline and upcoming therapies?
Insights into the product pipeline can significantly impact investor sentiment and expectations for future earnings.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate ADMA's potential for revenue growth based on its recent product advancements and market demand.
Supporting evidence
The company's historical EPS beat rate of 67% suggests stronger performance than expected.
Options pricing indicates a significant move, which could reflect underlying confidence in upcoming results.
Key risk
If revenue growth exceeds 15%, it could challenge the current cautious consensus.
Pre-commit to what would confirm each case.
The core thesis revolves around ADMA's ability to grow its revenue and successfully advance its product pipeline in a competitive biotechnology landscape.
Bull confirmed if
Demonstrating revenue growth of over 15% year-over-year would confirm the bull case.
Bear confirmed if
Revenue growth below 5% would support the bear case.
What the market is pricing for the move.
Implied Move
±26.9%
Historical Avg
±2.5%
The options market is pricing in a significant move of nearly 27%, suggesting that traders expect substantial volatility around the earnings report.
Options are pricing ±26.9% while ADMA has averaged ±2.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
61.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
92.76%
of float
Insider
1.97%
of float
Holders
437
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
38,355,684 sh · $388.9M
17.12%
4.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ADMA beats expectations, history suggests the stock could rise by around 0.27%, confirming strong operational performance.
In line / cautious
A cautious in-line report may lead to muted reactions, as investors await further clarity on future growth.
Miss
If the company misses expectations, history suggests a potential decline of about 3.59%, reflecting investor disappointment.
The lines on the call that would change the story.
State Street Corporation
17,116,022 sh · $173.6M
7.64%
21.5%
Vanguard Capital Management LLC
10,103,809 sh · $102.5M
4.51%
-2.0%
Vanguard Portfolio Management LLC
10,088,490 sh · $102.3M
4.50%
13.8%
Rubric Capital Management LP
9,339,414 sh · $94.7M
4.17%
416.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.